January 19, 2021
InnovationNews
Yposkesi develops gene therapies for the treatment of AAV and lentiviral vector. Read more
Yposkesi develops gene therapies for the treatment of AAV and lentiviral vector. Read more
Chairman & CEO
Alain Lamproye
IvexSol has been one of Yposkesi's top competitors. IvexSol's headquarters is in Worcester, Massachusetts, and was founded in 2019. Like Yposkesi, IvexSol also competes in the Biotechnology field. IvexSol generates 47% of Yposkesi's revenue.
January 19, 2021
InnovationNews
January 18, 2021
Biospectrum Asia
January 18, 2021
MarketScreener
No recent acquisitions found related to Yposkesi
No recent funding data found related to Yposkesi
No recent investments found related to Yposkesi
26, rue Henri Auguste-Desbrueres
Corbeil-Essonnes, Île-de-France91100
Driving Directions »